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Abstract:  Gold nanoparticles have potential applications in biomedicine, but one of the 
important  concerns  is  about  their  safety.  Most  toxicology  data  are  derived  from  in  vitro 
studies and may not reflect in vivo responses. Here, an animal toxicity study of 13.5 nm gold 
nanoparticles in mice is presented. Animal survival, weight, hematology, morphology, and 
organ index are characterized at different concentrations (137.5–2200 µg/kg) over 14–28 days. 
The results show that low concentrations of gold nanoparticles do not cause an obvious decrease 
in body weight or appreciable toxicity, even after their breakdown in vivo. High concentrations 
of gold nanoparticles induced decreases in body weight, red blood cells, and hematocrit. It 
was also found that gold nanoparticles administered orally caused significant decreases in 
body weight, spleen index, and red blood cells. Of the three administration routes, the oral and 
intraperitoneal routes showed the highest toxicity, and the tail vein injection showed the lowest 
toxicity. Combining the results of all of these studies, we suggest that targeted gold nanopartices 
by tail vein injection may be suitable for enhancement of radiotherapy, photothermal therapy, 
and related medical diagnostic procedures.
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Introduction
Colloidal gold nanoparticles have been proposed for diverse biomedical   applications 
due to their unique surface, electronic, and optical properties.1,2 Because of the 
strong and size-tunable surface plasmon resonance, fluorescence, and easy-surface 
functionalization, gold nanoparticles have been widely used in biosensors, cancer 
cell imaging, photothermal therapy, and drug delivery.3–9 Today, gold nanoparticles 
have been suggested to be potentially useful as a novel radiosensitizer in radiotherapy, 
because the strong photoelectric absorption and secondary electron caused by gamma 
or X-ray irradiation can accelerate DNA strand breaks.10–12 However, the potential 
toxicity of gold nanoparticles is still not completely understood.
In the past few years, the toxicity of nanomaterials, such as nanoparticles,   quantum 
dots, nanowires, and nanotubes has been reported.13–18 In general, the   toxicity of gold 
nanoparticles depends on their physical dimensions (such as size and shape) and   surface 
chemistry (such as coating). The biosafety of metallic gold is well   recognized and it 
has been used in vivo since the 1950s. However, functionalized gold nanoparticles 
show obvious cytotoxicity.19 To clarify these problems, the cytotoxicity of gold nano-
particles in human cells has been studied in detail, and the results have shown that gold 
nanoparticles are nontoxic up to 250 mM, while ionic gold shows obvious cytotoxicity 
at 25 mM.20 Similar results were also reported recently using gold nanoparticles as International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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radiotherapy in vitro.21–28 Despite these in vitro studies, there 
are few toxicologic reports of gold nanoparticles in animal 
models, which is the preferred system for toxicologic evalu-
ation of a novel agent and should be used to characterize the 
toxicity of gold nanoparticles. Actually, in vitro cultures can-
not replicate the complexity of an in vivo system or provide 
meaningful data about the response of a physiologic system 
to an agent. A case in point is carbon nanotubes.29 Manna 
et al found toxicity in vitro, whereas Schipper et al found 
no significant toxicity in vivo.30 Similarly, Sayes et al found 
that in vivo toxicology results for fullerenes were very dif-
ferent from in vitro data.31 The toxicity in vivo is determined 
by many parameters including dose, route of exposure, 
metabolism, excretion, and immune response. The toxico-
logic profiles of nanomaterials might also be determined by 
nanomaterial chemical composition, size, shape, aggregation, 
and surface coating.
Very recently, the size-dependent organ distributions of 
gold nanoparticles have been investigated, and the results 
showed that small gold nanoparticles of 5–15 nm had wider 
organ distribution than that of large gold nanoparticles of 
50–100 nm, and liver and spleen were the dominant targeted 
organs.32–37 Meanwhile, it has been found that gold nano-
particles with a long blood circulation time can accumulate 
in the liver and spleen, and have obvious effects on gene 
expression.38–40 Furthermore, the toxicity and biodistribu-
tion of polyethylene glycol (PEG)-coated gold nanoparticles 
have also been investigated, and the results showed that 20 
nm gold nanoparticles coated with TA-terminated PEG5000 
was more stable and had lower toxicity than 20 nm, 40 nm, 
or 80 nm gold nanoparticles coated with TA-terminated 
PEG5000.36,38,41,42 These in vivo results demonstrated that the 
possible toxicity of gold nanoparticles could occur in the 
body over short- and middle-term injection, and further 
toxicologic investigations and biologic changes are neces-
sary in vivo.
In previous work we have evaluated the irradiation 
stability and cytotoxicity of gold nanoparticles.43 Here, we 
carry out a toxicologic study of gold nanoparticles by using 
three different injected routes, namely oral, intraperitoneal, 
and tail vein injection. Gold nanoparticles of 13.5 nm with 
well-known good biocompatibility were chosen for this work. 
This experimental model can be applied to other engineered 
nanostructures, such as metallic nanoparticles, and the 
outcome of these studies will determine which injection route 
may be more suitable for photothermal therapy and radio-
therapy. Furthermore, the related hematologic parameters of 
organs have been analyzed.
Materials and methods
Fabrication of gold nanoparticles
The gold nanoparticles in Figure1 were fabricated 
following the classical method introduced by Turkevich 
et al.44 A volume of 100 mL of 0.01% chlorauric acid 
(HAuCl4⋅4H2O)   solution is refluxed, and 5 mL of 1% sodium 
citrate solution is added to the boiling solution. Reduction 
of gold ions by the   citrate ions is completed after five min-
utes, and the   solution is further boiled for 30 minutes and 
then left to cool to room temperature. This method yields 
spherical particles with an average diameter of about 13.5 
nm. Although the actual value of the mean size might vary 
slightly from each   preparation, the size distribution is always 
found to have a standard deviation of about 12%. Subse-
quently, the pH value of the citrate-coated gold nanoparticle 
solution is adjusted to 7.4 using dilute NaOH buffer solution, 
which is close to the physiologic environment of mice. The 
citrate-coated gold nanoparticle solution is filtered through 
0.45 µm filters to remove the precipitate, and the filtrate can 
be stored at 4°C in order to prevent aggregation. The gold 
  nanoparticle suspension (1 mL) is centrifuged at 13,500 rpm 
for 20   minutes, and the supernatant is removed. The remain-
ing gold nanoparticles are resuspended in 1 mL of ultrapure 
water, and gold nanoparticles with different concentrations 
can be obtained.
The size and morphology of the gold nanoparticles were 
analyzed by transmission electron microscopy using a Hitachi 
HF-2000 field emission high-resolution transmission elec-
tron microscopy operating at 200 kV . The optical absorption 
spectra in the wavelength range of 200–850 nm was measured 
using a DU800 spectrometer in a 5 mL glass cuvette.
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Figure 1 size and morphology of gold nanoparticles. The ultraviolet spectra of gold 
nanoparticles and transmission electron microscopic analysis (figure inset).
Note: gold nanoparticles were synthesized following the procedure described by 
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experimental design
Animals were purchased, maintained, and handled using 
protocols approved by the Institute of Radiation Medicine 
at the Chinese Academy of Medical Sciences. Male ICR 
mice were obtained from the Institute of Radiation Medicine 
laboratories at 11 weeks of age, were housed in a 12 hour/12 
hour light/dark cycle, and given food and water ad libitum. In 
the concentration-dependent toxicologic experiment, 36 mice 
were randomly divided into six groups (six in each group), 
comprising one control group and five experimental groups 
allocated to different doses of gold nanoparticles. Mice 
received oral administration of approximately 200 µL of gold 
nanoparticle solution at doses of 137.5 µg/mL, 275 µg/mL, 
550 µg/mL, 1100 µg/mL, and 2200 µg/mL, respectively. 
After daily injection, the mice were weighed and assessed 
for behavioral changes, and were sacrificed after injection 
of gold nanoparticles for 14 days.
Subsequently, the toxicologic experiments using the 
  different administration methods were performed at a dose 
of 1100 µg/mL. Thirty-six mice were randomly divided 
into six groups, comprising three kinds of administration 
and their respective control groups (six in each group). 
  Administration to the mice was performed using oral, 
intraperitoneal, and tail vein injection. Mice were injected 
with 200 µL of gold   nanoparticle solution and physiologic 
saline (contrast groups). Every two days after injection, 
mice were weighed and assessed for behavioral changes. 
The injections were well tolerated and no adverse effects 
were observed during the 24-hour observation period. 
Mice were sacrificed after injection of gold nanoparticles 
for 28 days.
hematology and sample collection
Using a standard saphenous vein blood collection technique, 
blood was drawn for hematology analysis (using potassium-
ethylenediaminetetraacetic acid collection tubes). Standard 
hematologic analysis was performed. For blood analysis, 
300 µL of blood was collected from the mice. At 14 and 
28 days, mice were sacrificed using isoflurane anesthetic 
and angiocatheter exsanguination with phosphate-buffered 
saline. One mouse from each group was fixed with 10% 
buffered formalin following phosphate-buffered saline 
  exsanguination. During necropsy, liver, kidneys, spleen, 
heart, lungs, brain, colon (section 10 mm in length), muscle 
(5 mm in diameter), thyroid, lymph nodes, and bone marrow 
(from the femur) were collected and weighed. The liver, kid-
neys, spleen, bone marrow, and lymph nodes were sectioned 
from the fixed mice.
Microscopic properties of gold nanoparticles in the bone 
marrow and blood cells were obtained after oral administra-
tion for 14 days at a dose of 2200 µg/mL. For the transmission 
electron microscopy analysis, the solution was centrifuged 
and the pellet was fixed with 2.5% glutaraldehyde in 0.03 M 
potassium phosphate buffer at pH 7.4. The cells are then fixed 
with 1% osmium tetroxide in 0.1 M sodium cacodylate buffer 
and 0.5% uranyl acetate in 0.05 M maleate buffer. Cells were 
then dehydrated in a graded series of ethanol and   embedded 
in Epon. Ultrathin sections were cut and transferred on 
200-mesh uncoated copper grids, stained with uranyl acetate, 
counterstained with lead citrate, and observed with Hitachi 
HF-2000 field emission high-resolution transmission electron 
microscopy operating at 200 kV .
Results and discussion
effects on body weight
Figure 2 shows the body weight variations of the mice after 
oral administration at different concentrations. It can be seen 
that oral administration of gold nanoparticles in the dose 
range 137.5–275 µg/kg did not cause mortality, and body 
weight was slightly higher compared with the control group 
during a one-day observation period. At the dose range of 
550–2200 µg/kg, the body weight of the mice was slightly 
but significantly lower than in the control group. During the 
study period, treatment with gold nanoparticles for 14 days 
did not cause obvious adverse effects on growth because 
no statistically significant differences in body weight gain 
were observed between the gold nanoparticle-treated mice 
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Figure 2 Body weight changes for mice treated with gold nanoparticles at doses 
of 137.5–2200 µg/kg.
Note:  Body  weight  was  measured  every  two  days.  each  point  represents  the 
mean ± standard deviation of six mice. Data were analyzed by student’s t-test 
and the differences between the doses and control group for each organ are not 
significant (P . 5%).International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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and control mice. Furthermore, no abnormal clinical signs 
or behavior were detected in either the control or treated 
groups. Considered together, gold nanoparticle treatment 
did not induce any apparent toxicity in mice. Necropsy at the 
end of the experiment did not show any macroscopic organ 
changes in the six groups. It should be noted, however, that 
injection of gold nanoparticles caused transient reversible 
changes in body weight of the mice within 10–14 days after 
injection. Adverse vascular or behavioral reactions were 
not observed.
Body weight variation within 28 days at a dose of 
1100 µg/kg is shown in Figure 3. It can be seen that body 
weight after tail vein injection was slightly decreased 
  compared with the control group, and no statistically 
significant differences were observed by tail vein injection, 
which indicates low toxicity of gold nanoparticles via this 
route. Intraperitoneal injection induced a slight decrease in 
body weight, and oral administration showed an obvious 
effect on body weight. Statistical differences were observed 
for both intraperitoneal injection and oral administration. 
The decrease in body weight after oral administration was 
particularly obvious after 15 days of injection compared with 
that after 1–14 days. Therefore, the oral and intraperitoneal 
injections may induce some toxicity, while the tail vein 
injection may induce lower toxicity.
It is well known that size, shape, and surface capping (or 
modification) of nanoparticles can induce a different toxicity 
effect in mice. However, the toxicologic effect of the different 
administration routes is still not clear. Oral   administration 
may cause some effects on the digestive   system, while tail 
vein injection mainly acts on blood and related organs. 
Indeed, previous toxicity investigations also showed that 
gold nanoparticles after oral administration had strong 
gastrointestinal persorption effects.45 It has been shown that 
oral delivery of nanoparticles may affect the mucosa due 
to the morphologic and physiologic absorption barriers in 
the gastrointestinal tract.46 In our experiment, no significant 
damage to the stomach was found, which indicates good 
absorption and digestion after gold nanoparticle injection. 
However, slight damage to the intestine, such as intestinal 
tympanites, was observed in two of six orally injected mice, 
which may be the main reason for the high toxicity of the 
gold nanoparticles. Therefore, the gastrointestinal reaction 
and absorption would play an important role in oral admin-
istration of gold nanoparticles. Intraperitoneal injection is 
generally preferred when intravenous injection is not feasible. 
It is well known that drug absorption by intraperitoneal injec-
tion is good and rapid due to the dense blood vessels and 
lymph in the murine peritoneum. Indeed, we found that the 
effect on body weight by intraperitoneal injection was less 
than that by oral administration.
Most recently, intraperitoneal injection of gold nano-
particles has been investigated by Lasagna-Reeves et al 
and the results showed toxicity was low at the dose range 
320–3200 µg/kg/day.47 No evidence of toxicity was observed 
in any of the diverse studies, including survival, behavior, 
animal weight, organ morphology, blood biochemistry, 
and histology. However, it should be noticed that the toxi-
cologic reactions in their experiments were carried out by 
consecutive injections (40–400 µg/kg/day).47 Overall, gold 
nanoparticles by intraperitoneal injection were less toxic 
than oral administration at the dose of 1100 µg/kg. Tail vein 
injection is widely used to study the toxicologic effects of 
gold nanoparticles (see Table 1). The benefit of performing 
a tail vein injection is that it is a less invasive procedure for 
the animal. We found that the lowest toxicity of the gold 
nanoparticles was associated with the tail vein injection. The 
previous biodistribution and pharmacokinetics of pegylated 
gold nanoparticles also showed the highest colloidal stability, 
nonaggregation, and lack of toxicity of 20 nm PEG-coated 
gold nanoparticles.41 Meanwhile, recent work by Cho et al 
showed that 13 nm PEG-coated gold nanoparticles could 
induce acute inflammation and apoptosis in the liver, and 
these nanoparticles were found to accumulate in the liver 
and spleen for up to seven days after tail vein injection and 
to have long blood circulation times.38 Cho et al showed 
that gold nanoparticles induced potential long-time organ 
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Figure 3 Body weight changes in mice treated with gold nanoparticles 1100 µg/kg 
by using three administration routes, ie, oral, intraperitoneal, and tail vein injection.
Note: each point represents mean ± standard deviation. Data were analyzed by 
Student’s t-test. *Represents significant difference from the control group (P , 0.05).International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Table 1 A summary of in vivo toxicity of gold nanoparticles
Group Surface coating Size  Study period Dose Method of  
administration
hillyer45 
hainfeld10 
de Jong32 
sonavane33 
Kim34 
chen35 
 
cho36,38 
semmler-Behnke37 
 
Balasubramanian39 
 
Zhang41 
Lipka42 
 
Lasagna-reeves47 
sadauskas50 
 
Fent53 
 
This work
Naked 
PBs buffered 
Naked 
Naked 
PBs buffered 
Naked 
 
hs-Peg 
Naked 
 
Naked 
 
Peg-TA or Peg-sh 
Peg 
 
Naked 
Naked 
 
gum arabic- and 
maltose-coated 
Naked
4, 10, 28, and 58 nm 
1.9 nm 
10, 50, 100, and 250 nm 
15, 50, 100, and 200 nm 
20 and 100 nm 
3, 5, 8, 12, 17, 37,  
and 50 nm 
4, 13, and 100 nm 
1.4 and 18 nm 
 
20 nm 
 
20, 40, and 80 nm 
5 nm 
 
12.5 nm 
40 nm 
 
6–10 and 15–20 nm 
 
13.5 nm
7 days 
5 min 
24 hours 
24 hours 
24 hours 
21 days 
 
4–30 min, 1–7 days 
24 h 
 
1 day, 1 week, 
1 and 2 months 
48 h 
1–24 h 
 
8 days 
1day, 1, 3,  
and 6 months 
1–24 hours and 
7–32 days 
14, 28 days
20,000 µg/kg 
1350 µg/kg 
77–120 µg/kg 
1000 µg/kg 
1000 µg/kg 
8000 µg/g/week 
 
170–4200 µg/kg 
54–530 µg/kg 
 
10 µg/kg 
 
100–4400 µg/kg 
570–870 µg/kg 
 
40–400 µg/kg/day 
1400–1600 µg/kg 
 
2000 µg/kg 
 
137.5–2200 µg/kg
Oral 
Tail vein 
Tail vein 
Tail vein 
Tail vein 
Intraperitoneal 
 
Tail vein 
Intratracheal 
and intravenous 
Intravenous 
 
Tail vein 
Tail vein and 
intratracheal 
Intraperitoneal 
Tail vein 
 
Intravenous 
 
Tail vein, oral, 
intraperitoneal
Abbreviations: Peg, polyethylene glycol; PBs, phosphate-buffered saline.
damage and toxicity,38 and their overall results showed that 
the toxicity by tail vein injection was the lowest among the 
three injection routes.
Morphology of gold nanoparticles  
in blood and bone marrow cells
Figure 4 shows transmission electron microscopy images 
of the gold nanoparticles in blood and bone marrow cells 
after oral administration of 2200 µg/kg for 14 days. For a 
single cell, multiple vesicles containing gold nanoparticles 
were readily observed. Within the vesicles, the gold nano-
particles appeared to be monodispersed, which is consistent 
with previous investigations.48 Figure 4a shows the overall 
micromorphology of single gold nanoparticles per vesicle 
diameter. Gold nanoparticles are seen in the blood cells 
  easily, which is related to the size of the nanoparticles. 
  Figure 4b shows the transmission electron microscopy image 
of bone marrow cells, which is similar to that of blood cells. 
Many gold nanoparticles can be observed outside of the cell 
membrane, and the average size is about 10–15 nm. Of note, 
the gold nanoparticles could still be found in blood and 
  marrow bone cells after 14 days of oral administration, which 
indicates a long blood circulation time for gold nanoparticles, 
which is in good agreement with previous reports.38–40 It has 
been suggested that the interaction between protein and 
gold nanoparticles may be closely related to the toxicity 
of the nanoparticles.27 The surface of the citrate-stabilized 
gold nanoparticles probably contains a variety of serum pro-
teins. Many of these serum proteins (eg, α and β proteins) 
Blood cell Bone marrow cell
Figure 4 Transmission electron microscopy figures for gold nanoparticles in bone 
marrow and blood cells 14 days after oral administration at 2200 µg/kg.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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are known to be taken up by cells.48 It has been shown that 
gold nanoparticles strongly associate with essential blood 
  proteins (such as albumin, fibrinogen, γ-globulin, histone, and 
  insulin), and the degree of binding between the nanoparticles 
and proteins is increased, and that the degree of cooperativity 
of particles decreases with increasing size.49 Furthermore, 
these interactions, such as enhanced binding, can induce 
conformational change of the proteins. Thus, further study 
is necessary to understand how the mechanism of the protein 
adsorption process changes the protein conformation and the 
tendency for aggregation of gold nanoparticles.
Organ indices and hematology results
Table 2 gives the organ weights of mice at different nano-
particle doses to illustrate the effect of gold nanoparticles 
on organs. It can be seen that the weights of the heart, liver, 
spleen, lung, kidneys, and brain are decreased at the dose 
range 550–1100 µg/kg. However, the weight of the thymus 
is increased with increases in nanoparticle concentration, but 
no statistically significant differences are found in these data. 
To further investigate the organ reaction, the organ indices 
for thymus and spleen are presented in Figure 5a. To examine 
the grade of changes explicitly caused by gold nanoparticles, 
the spleen and thymus indices (Sx) can be defined as:
S
Weightof experimental organ 
Weightof experimental anima
x
mg
=
()
l l () g
The average values of thymus and spleen indices in the 
control group were 1.925 and 3.73, respectively. The thymus 
and spleen indices in the treated group increased to 2.65 and 
4.5, respectively, at a gold nanoparticle dose of 2200 µg/kg. 
There are still no statistically significant differences between 
the treated group and the control group, which shows that 
injections of gold nanoparticles at different doses do not 
cause obvious toxicologic effects on both the thymus and 
spleen. Table 3 shows the variations in organ weight and 
index by the different injection methods at the dose of 
1100 µg/kg. It can be seen that the weights of liver, lung, 
spleen, kidneys, and heart decrease according to the differ-
ent injection routes. Some differences for brain and thymus 
weights were observed with oral administration. Thymus 
weight was slightly decreased with oral administration and 
tail vein injection, and slightly increased by intraperitoneal 
injection. However, these results showed no statistically 
significant difference. Figure 5b gives the thymus and spleen 
indices after different injection routes. The thymus index 
shows little variation with the different injection routes. The 
spleen index is decreased by intraperitoneal injection and 
tail vein injection, and increased by oral administration. In 
particular, a statistically significant difference between the 
oral administration group and the control group is observed, 
which indicates that the immune system has been affected by 
oral gold nanoparticle administration. Taken together with 
the previous body weight variation, it seems that the oral 
administration route can affect the gastrointestinal system 
and furthermore can damage the immune system. More-
over, it implies that the spleen is one of the target organs 
for gold nanoparticles, which is in good agreement with 
previous work.32–42,50 The liver and spleen are considered 
two dominant organs for biodistribution and metabolism of 
gold nanoparticles.32–42
To quantify the toxicity of gold nanoparticles, the next 
important step is assessment of standard hematologic param-
eters, ie, platelet count, hematocrit, hemoglobin, red blood 
cell count, and white blood cell count.
Concentration-dependent hematology results are 
presented in Figure 6a. Hematocrit and red blood cells 
significantly decrease at gold nanoparticle doses of 550 
and 1100 µg/kg, respectively, but they do not indicate a 
Table 2 Weight of organs for liver, lung, spleen, kidneys, brain, heart, and thymus after oral administration of different doses 
(137.5–2200 µg/kg) for 14 days
Dose (μg/kg) Control  137.5 275 550 1100 2200
heart (g)  0.194 ± 0.048 0.185 ± 0.037 0.167 ± 0.057  0.105 ± 0.017 0.104 ± 0.027  0.099 ± 0.031
Liver (g)  1.431 ± 0.036 1.437 ± 0.433 1.321 ± 0.452 1.206 ± 0.197 1.348 ± 0.074 1.071 ± 0.012
Spleen (g)  0.120 ± 0.004 0.126 ± 0.009 0.160 ± 0.068 0.109 ± 0.005 0.103 ± 0.047 0.095 ± 0.002
Lung (g)  0.305 ± 0.060 0.215 ± 0.035 0.246 ± 0.052 0.235 ± 0.019 0.140 ± 0.040 0.150 ± 0.015
Kidneys (g)  0.215 ± 0.048 0.200 ± 0.057 0.221 ± 0.054 0.135 ± 0.001 0.135 ± 0.011 0.122 ± 0.002
Thymus (g)  0.034 ± 0.002 0.067 ± 0.011 0.062 ± 0.008 0.054 ± 0.013 0.048 ± 0.003 0.056 ± 0.011
Brain (g) 0.391 ± 0.028 0.410 ± 0.003 0.389 ± 0.043 0.349 ± 0.009 0.370 ± 0.045 0.213 ± 0.006
Data were analyzed by Student’s t-test and the differences between the doses for each organ were not significant (P . 5% versus controls). All values represent the   
mean ± standard deviation for six mice.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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concentration-dependent trend associated with treatment. 
Hemoglobin, platelet count, and white blood cells have 
changed, but no statistically significant difference is observed. 
The hematologic effects of the different injection methods 
for the gold nanoparticles are shown in Figure 6b. It can be 
observed that hemoglobin, red blood cells, and white blood 
cells decrease with the three different injection routes, but 
the decrease was only statistically significant for red blood 
cells. This indicates that the different injection routes did not 
induce significant differences in platelet count, hemoglobin, 
or white blood cells. Red blood cells show a significant differ-
ence after oral administration, intraperitoneal injection, and 
tail vein injection. Oral administration and intraperitoneal 
injection induce a decrease in red blood cells, and the tail 
vein injection does not cause any significant change in this 
parameter.
Red blood cells are derived from hemopoietic stem cells in 
bone marrow. Following a series of maturation steps, directed 
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Figure 5 Thymus and spleen indices of mice after oral administration by different doses (137.5–2200 µg/kg) (A) after 14 days and the different injection routes at the dose 
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Abbreviations: OrAL, oral administration; INTer, intraperitoneal injection; TAIL, tail vein injection. International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
778
Zhang et al
mainly by erythropoietin, red cells enucleate and enter the 
circulatory system. Thus, the variation in red blood cells can be 
related to the hematopoietic system. Decreases in   hematocrit 
and red blood cells are found at the high dose in Figure 6a. 
It can be determined that the high dose of gold nanoparticles 
can also have an obvious effect on the hematopoietic sys-
tem. The in vitro toxicologic experiments indicate that the 
10–100 µg/mL dose range is nontoxic for 13.5 nm naked gold 
nanoparticles, although the different cell lines may induce 
slight deviation.20–26,43 The dose of gold nanoparticles in vivo 
(137.5–2200 µg/kg) is obviously lower than that in vitro. The 
difference in toxicologic effects between in vivo and in vitro 
systems is evident. In addition, the three routes of injection can 
produce different reactions in mice. Oral administration causes 
damage to the gastrointestinal system, and further affects the 
immune system via splenic metabolism. However, the detailed 
mechanism is still not clear and further study is necessary. 
All these abnormal responses in weight, spleen index, and red 
blood cells show that the oral administration route produces 
the highest toxicity compared with intraperitoneal and tail 
vein injection. For the intraperitoneal injection, the decrease 
in red blood cells still indicates damage to the hemopoietic 
system. The tail vein injection has the least effect on hematol-
ogy, indicating the lowest toxicity. When gold nanoparticles 
are administered, the first physiologic system they interact 
with is the blood and its components. Indeed, gold nanopar-
ticles can induce an inflammatory response and increase or 
decrease the activity of the immune system and alter related 
hematologic factors such as blood cell counts.51,52 Therefore, 
it is necessary to address these phenomena to reveal further 
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Figure 6a hematology results from mice treated with gold nanoparticles and the control group after 14 days oral administration by different doses (137.5–2200 µg/kg). 
Note: Bars represent mean ± standard deviation. Data were analyzed by Student’s t-test. *Represents significant difference from the control group (P , 0.05).
Abbreviations: PLT, platelets; hcT, hematocrit; hgB, hemoglobin; rBc, red blood cells; WBc, white blood cells.
Table 3 Weight of organs for liver, lung, spleen, kidneys, brain, heart, and thymus by using oral, intraperitoneal, and tail vein injection 
at doses of 1100 µg/kg at 28 days
Dose 
(μg/kg)
Control 
(Oral)
Oral 
administration
Control 
(Intraperitoneal)
Intraperitoneal 
injection
Control 
(Tail vein)
Tail 
vein injection
Heart (g) 0.195 ± 0.025 0.082 ± 0.011 0.237 ± 0.005 0.222 ± 0.005 0.202 ± 0.002 0.132 ± 0.058
Liver (g) 2.234 ± 0.339 1.329 ± 0.177 1.853 ± 0.086 1.832 ± 0.176 1.643 ± 0.099 1.157± 0.226
Spleen (g) 0.176 ± 0.042 0.342 ± 0.058 0.129 ± 0.042 0.123 ± 0.011 0.138 ± 0.036 0.061 ± 0.003
Lung (g) 0.278 ± 0.049 0.243 ± 0.057 0.521 ± 0.022 0.198 ± 0.024 0.209 ± 0.078 0.191 ± 0.012
Kidneys (g) 0.232 ± 0.044 0.162 ± 0.028 0.248 ± 0.038 0.237 ± 0.068 0.235 ± 0.036 0.182 ± 0.009
Thymus (g) 0.095 ± 0.020 0.060 ± 0.005 0.036 ± 0.006 0.068 ± 0.001 0.076 ± 0.008 0.022 ± 0.002
Brain (g) 0.411 ± 0.014 0.387 ± 0.013 0.437 ± 0.002 0.450 ± 0.043 0.412 ± 0.025 0.422 ± 0.003
Data were analyzed by Student’s t-test and the differences between the administration routes for each organ are not significant (P . 5% versus controls). All values represent 
the mean ± standard deviation for six mice.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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the mechanism of interaction between biologic tissue and gold 
nanoparticles in vivo.
Conclusion
An animal toxicity study using 13.5 nm gold nanoparticles 
in mice was carried out. Animal survival, animal mass, 
hematology, and morphology were characterized at different 
concentrations (137.5–2200 µg/kg) over 14–28 days. The 
results show that gold nanoparticles at low concentrations 
do not cause appreciable toxicity even after their breakdown 
in vivo over time. Increasing concentrations of gold nanopar-
ticles induce decreases in weight but no significant statistical 
difference is observed. Obvious effects on organ index have 
been observed at high concentration. Moreover, of the three 
different administration routes, the oral and intraperitoneal 
injection show the highest toxicity, and tail vein injection 
shows the least toxicity. Considering the results of all of these 
studies, targeting gold nanoparticles by tail vein injection is 
promising for possible biomedical application.
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